Solid Biosciences(SLDB) - 2025 Q4 - Annual Results

Capital Raise and Securities Offering - The Company is issuing an aggregate of 14,973,257 shares of Common Stock at a purchase price of $5.61 per share[42] - The Company is also offering pre-funded warrants to purchase an aggregate of 27,807,482 shares of Common Stock, with an exercise price of $0.001 per Warrant Share[42] - The total purchase price for the Pre-Funded Warrants is $5.609 per Warrant Share[42] - The Closing Date for the transaction will occur no later than the fifth Trading Day after the date of the Agreement[43] - Each Investor will receive a number of Shares and Pre-Funded Warrants as specified in Exhibit A attached to the Agreement[46] - The Company will provide registration rights for the Shares and Warrant Shares under the 1933 Act and applicable state securities laws[4] - The Agreement is executed in reliance upon the exemption from securities registration under Section 4(a)(2) of the 1933 Act[4] - The Company is authorized to issue 240,000,000 shares of Common Stock, and all issued shares are fully paid and nonassessable[50] - The Company has no agreements with any Investor for more favorable terms than those set forth in the current agreement[95] - The Company has not conducted any general solicitation or advertising in connection with the offer or sale of its securities[75] - The Securities will be acquired for the Investor's own account and not for resale or distribution in violation of the 1933 Act[98] - Investors acknowledge they can bear the economic risk and complete loss of their investment in the Securities[99] - The Securities are characterized as "restricted securities" under U.S. federal securities laws[101] - Investors understand that the Securities have not been registered under the 1933 Act and may not be transferred unless certain conditions are met[102] - Each Investor is an institutional "accredited investor" as defined under the 1933 Act[103] - The Company must obtain all necessary consents and approvals for the consummation of the purchase and sale of the Placement Securities[115] - The Company shall have filed with Nasdaq a Listing of Additional Shares notice form for the listing of the Shares and the Warrant Shares[116] - The Company is obligated to sell and issue Placement Securities at the Closing, subject to the fulfillment of specific conditions[122] - Each Investor must execute and deliver the Registration Rights Agreement prior to the Closing[124] - The Company will not issue shares of Common Stock or Common Stock Equivalents for 30 days after the Closing Date without consent from Required Investors[133] - The Company agrees to indemnify each Investor against losses, claims, damages, and liabilities arising from breaches of representation or warranty[140] - The Company is responsible for any placement agent's fees or broker's commissions related to the transactions[135] - The Company must ensure that no stop order or suspension of trading is imposed by Nasdaq or any regulatory body[121] - The Company must provide written notice to Investors if any conditions for Closing become incapable of fulfillment[126] - The Company will request the transfer agent to remove restrictive legends from shares sold by Investors under certain conditions[129] - The Company must ensure that the aggregate number of shares issued in connection with unaffiliated third-party transactions does not exceed 10% of the total shares outstanding after Closing[133] Financial Performance and Projections - Solid Biosciences Inc. reported a significant increase in revenue, reaching $50 million for the fiscal year, representing a 25% year-over-year growth[1] - Solid Biosciences Inc. anticipates a revenue guidance of $60 million for the next fiscal year, indicating a projected growth of 20%[1] - The company reported a 10% increase in gross margin, now standing at 65%, due to improved operational efficiencies[1] Research and Development - The company is investing $10 million in R&D for new product development, focusing on gene therapies and innovative treatment solutions[1] - Solid Biosciences Inc. has established partnerships with three leading research institutions to accelerate its product development pipeline[1] Market Expansion and Strategic Initiatives - The company has expanded its user base by 15%, now serving over 200,000 active users across its platforms[1] - Solid Biosciences Inc. plans to enter two new international markets by the end of the next fiscal year, aiming to increase its global footprint[1] - The company has completed a strategic acquisition of a biotech firm for $30 million, enhancing its capabilities in genetic research[1] - Solid Biosciences Inc. has launched a new product line that is expected to generate an additional $15 million in revenue within the first year[1] - The company is implementing a new marketing strategy with a budget of $5 million to enhance brand awareness and customer engagement[1] Compliance and Corporate Governance - The Company has confirmed that it is duly organized and in good standing under the laws of its jurisdiction of incorporation[48] - The Company has taken all necessary corporate actions for the authorization, execution, and delivery of the Transaction Documents[49] - The Company’s subsidiaries are fully owned and in good standing, with no expected Material Adverse Effect from their operations[48] - The financial statements included in SEC Filings comply with applicable accounting requirements and present fairly the consolidated financial position of the Company[71] - The Company is in compliance with applicable Nasdaq continued listing requirements, with no pending or threatened proceedings regarding delisting[73] - The Company has established and maintains disclosure controls and procedures to ensure material information is communicated to its principal executive and financial officers[81] - There have been no material weaknesses in the Company's internal control over financial reporting since the end of the most recent audited fiscal year[81] - The Company is in compliance with all applicable Health Care Laws, including the Federal Food, Drug, and Cosmetic Act and HIPAA[87] - The Company has not received any written notices from Regulatory Authorities requiring termination or modification of any preclinical studies or clinical trials[86] - The Company has implemented reasonable controls to protect the confidentiality and security of sensitive data, with no known breaches or unauthorized accesses[92] - The Company is in compliance with all applicable data privacy laws, including the EU General Data Protection Regulation (GDPR)[93] - The Company has not engaged in any actions designed to manipulate the price of its securities[89] - The Company is not required to register as an "investment company" under the Investment Company Act of 1940[85]